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Background: The first positive patient with influenza A (H1N1) was recorded in March 2009 
and the pandemic continued with new outbreaks throughout 2010. This study’s objective was 
to quantify the total cost of inpatient care and identify factors associated with the increased cost 
of the 2009–2010 influenza A pandemic in comparison with nonviral respiratory infection.
Methods: In total, 133 positive and 103 negative H1N1 patients were included from three 
tertiary care hospitals during the two waves of H1N1 in 2009 and 2010. The health costs for 
protective equipment and pharmaceuticals and hospitalization (medications, laboratory, and 
diagnostic tests) were compared between H1N1 positive and negative patients.
Results: The objective of the study was to quantify the means of daily and total costs of inpa-
tient care. Overall, cost was higher for H1N1 positive (€61,0117.72) than for H1N1-negative 
patients (€464,923.59). This was mainly due to the protection measures used and the prolonged 
hospitalization in intensive care units. In H1N1-negative patients, main contributors to cost 
included additional diagnostic tests due to concern regarding respiratory capacity and labora-
tory values, as well as additional radiologic and microbial culture tests. The mean duration of 
hospitalization was 841 days for H1N1 positive and 829 days for negative patients.
Conclusion: Cost was higher in H1N1 patients, mainly due to the protection measures used 
and the increased duration of hospitalization in intensive care units. An automated system to 
monitor patients would be desirable to reduce cost in H1N1 influenza.
Keywords: cost effect, H1N1, health care resource utilization, respiratory infection
Introduction
Since May 2009, the pandemic influenza A (H1N1) virus has been spreading throughout 
the world and has reached pandemic proportions.1–5 The World Health Organization 
promptly advised northern countries to prepare for a second wave of pandemic.6 To date, 
this second wave has been documented in most countries worldwide.7,8   Importantly, 
not only are influenza viruses highly contagious, but they can also mutate, developing 
resistance to standard treatment.9–11 The incidence, clinical characteristics, and factors 
affecting patient outcome of the first wave have already been described.12–16
According to UK data, 2% of influenza patients require hospitalization and 
10%–25% treatment in an intensive care unit (ICU).15,17–19 The average patient age with 
health complications due to influenza A infection is lower than seasonal influenza.20 
Although the number of H1N1-positive patients was lower in 2010, hospitalization 
rates and the proportion of hospitalized cases admitted to ICU were higher than the 
numbers and rates of 2009. The reasons for these differences are not yet completely 
understood. What is clear, however, is that hospitalization, including precautionary 
measures and treatment, may increase health cost.
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The purpose of this multicenter retrospective study was 
to quantify the means of daily and total costs of inpatient 
care and identify any major factors associated with increased 
cost of the 2009–2010 H1N1 virus infection versus nonviral 
respiratory infection.
Patients and methods
Study design
This was a respective study of the records of patients 
admitted during 2009 and 2010 to three tertiary hospitals 
who were either H1N1 positive or H1N1 negative but with 
respiratory infection. During these 2 years, patients were 
admitted through the emergency room with suspicion of 
H1N1 virus. Data relating to laboratory findings, medica-
tions, and protection measures of admitted patients were 
analyzed. The present analysis comprised only patients for 
whom full cost data were evaluable. In total, 236 patients 
were enrolled. These included 133 (77 male and 56 female) 
H1N1-positive patients and 103 (36 males and 67 females) 
H1N1-negative patients.
Control measures and personal 
protective equipment
H1N1-positive patients were hospitalized in units with nega-
tive pressure especially designed for isolating patients with 
airborne viral infections8,9,12,13 (Figures 1 and 2). For health 
care personnel in close contact (defined as working within 
6 feet of the patient or entering into a small enclosed airspace 
shared with the patient) with suspected or confirmed 2009 
H1N1 influenza patients, standard precautions included the 
use of nonsterile gloves for any contact with potentially 
infectious material, followed by hand hygiene immediately 
after glove removal, and the use of gowns along with eye 
protection for any activity that might generate splashes of 
respiratory secretions or other infectious material.
Study sample
All patients with flu-like symptoms (ie, sore throat, cough, 
rhinorrhea, or nasal congestion) and fever .37.5°C were 
admitted to the units of infectious diseases and had pha-
ryngeal or nasopharyngeal swabs taken. Swabs were tested 
with real-time reverse-transcriptase-polymerase chain reac-
tion.21–24 Data on underlying diseases were also recorded; 
diseases included chronic obstructive pulmonary disease 
(COPD), cancer, asthma, coronary heart disease, and dia-
betes mellitus. The criteria for discharge were absence of 
hypoxemia, normal chest X-ray, and a temperature ,37°C for 
1 day without antipyretic treatment. Upon discharge, they did 
not exit the negative pressure chambers to enter the general 
medical wards, but continued their hospitalization until 
hospital discharge. This was due to public prejudice about 
H1N1, as evidenced further by the fact that some patients 
with H1N1 even left the hospital because they did not want 
to become stigmatized. Patients negative for H1N1 were 
admitted to the general medical wards and were discharged 
from there. A second reverse-transcriptase-polymerase chain 
reaction test for H1N1 was not performed (Table 1).
Cost analysis
Contributors to health cost were precaution measures, 
pharmaceuticals administered, length of hospitalization 
(separately assessed in ICU and non-ICU), and diagnostic 
examinations (ie, laboratory, radiologic). Expenditure was 
calculated in Euros. The average prices of drugs were based 
on Greek retail prices. Hospitalization costs including nurs-
ing were calculated based on data provided by the hospital’s 
health economy personnel. The cost of diagnostics and 
drugs was the same in all hospitals, with some very minor 
differences in the costs of hospital-based care. This is due 
to the organization of the Greek health care system, which 
reimburses expenses via a national health insurance scheme 
in a uniform way.
Statistical analysis
Analysis was carried out with the use of the SPSS statistical 
software package (v 17.01; SPSS Inc, Chicago, IL).   Continuous 
variables were presented as mean ± standard deviation or 
median (with interquartile range). For categorical variables, 
the percentages of patients in each category were calculated. 
Unpaired t-test was used in normally distributed quantitative 
variables to compare mean values. Chi square test was used to 
compare qualitative variables (frequencies in characteristics). 
A P-value of ,0.05 was considered significant.
Results
Patients’ characteristics
In H1N1-positive patients, the mean age was 38.65 years, 
while it was 57.90 years in H1N1-negative patients. The 
frequency of obesity (ie, body mass index $30)25 was the 
same in the two groups (52.4% versus 51.1%). Among 
H1N1 patients, 46 (43.5%) had underlying respiratory 
disease (asthma, 22 [16.5%]; COPD, 21 [15.7%]; idio-
pathic pulmonary fibrosis, three [2.2%]), compared with 
33 (32%) negative patients (asthma, 9 [8.7%]; COPD, 
24 [23.3%]). In H1N1-positive patients, comorbidities were 
as follows: congestive heart failure, 18 (13.5%); diabetes 
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Figure 1 (A) Entrance (↓) and exit (–), (B) entrance, (C) negative pressure room, (D) exit. 
Note: Photos by Paul Zarogoulidis, Unit of Infectious Diseases, University General Hospital of Alexandroupolis, Thrace, Greece.
Figure 2 Protection measures: (A) protective glasses, (B) 3M™ protective mask without micro filter, (C) 3M™ protective mask with micro filter, (D) protective cup,   
(E) protective clothing.
Note: Photos by Paul Zarogoulidis, Unit of Infectious Diseases, University General Hospital of Alexandroupolis, Thrace, Greece.
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mellitus, 20 (15%); and cancer, ten (7.5%). H1N1-negative 
patients’ comorbidities were: congestive heart failure, 
44 (42.7%); diabetes mellitus, 20 (19.4%); and cancer, 
six (5.8%). Nine (6.8%) H1N1-positive patients and four 
(3.9%) H1N1-negative patients had to be admitted to the 
ICU (Tables 1 and 2).
Pharmaceuticals
First, the cost of the oseltamivir 75 mg regimen was recorded. 
In H1N1-positive patients, €4655.32 was spent, in contrast 
to €1324.58 in H1N1-negative patients. The cost of mac-
rolide treatment was €1927.36 for positive and €1588.17 
for H1N1-negative patients. The cost of quinolone treatment 
was €2550.84 for H1N1-positive patients and €2404.24 for 
H1N1-negative patients. Aerosol and oxygen therapy were 
used freely, as judged by the clinicians. Aerosol therapy was 
provided with jet nebulizers and a combination of budesonide 
and ipratropium bromide was administered daily. Respiratory 
distress (PO2 , 60 mmHg) for H1N1 was noted in 20/133 
(15%) positive and 52/103 (50.5%) negative patients, but this 
treatment was not included in the cost, since it is provided 
throughout hospitalization without any additional charge. 
Furthermore, €3427.20 was spent for aerosol therapy for 
H1N1-positive patients and €2833.6 for H1N1-negative 
patients (Table 3).
Diagnostic examinations
Chest X-ray findings upon admission were implemented 
in 42 (31.6%) positive and 103 (100%) negative patients. 
Mean saturation (SpO2%) was 94.62% in positive and 
93.06% in negative patients. Mean partial oxygenation was 
74.83 mmHg for positive and 65.55 mmHg for negative 
patients. Respiratory distress (PO2 , 60 mmHg) was noted 
in 20 (15%) positive and 52 (50.5%) negative patients. The 
cost for arterial blood gas was €2352 for positive and €2012 
for negative patients. The chest X-ray cost was €2320 for 
positive and €2660 for negative patients. Blood biochem-
istry cost, which included complete blood count, glucose, 
Table 1 Patients’ characteristics and clinical data
With/Without SD P
H1N1 positive H1N1 negative
Age (years) 38.65 57.90 16.974/23.645 ,0.001
Chest X-ray with findings upon admission 42 (31.6%)/91 (68.4%) 103 (100%)/0 (0%) ,0.001
Days under oseltamivir 5.4 42.00 2.542/0.00 ,0.001
Days of hospitalization 6.32 8.05 3.336/4.418 NS
Patients with obesity 68 (51.1%)/65 (48.9%) 54 (52.4%)/49 (47.6%) NS
PO2 upon admission (mmHg) 74.83 65.55 13.888/14.156 NS
SPO2 upon admission (mmHg) 94.62 93.06 12.308/16.64 0.001
Sex (male/female) 77/56 (57.9%/42.1%) 57/46 (55.34%/44.66%) NS
Patients administered macrolides 96 (72.2%)/37 (27.8%) 60 (58.3%)/43 (41.7%) 0.005
Patients administered quinolones 53 (39.8%)/80 (60.2%) 43 (41.7%)/60 (58.3%) NS
Patients changed/added quinolones  
from/to macrolides*
16/96 –
Respiratory distress upon admission 20 (15%)/113 (85%) 52 (50.5%)/51 (49.5%) ,0.001
Patient with respiratory disease background 46 (34.5%)/87 (65.4%) 33 (32%)/70 (67.9%) NS
Intensive care unit admission 9 (6.7%) 4 (3.8%) NS
Asthma 22 (16.5%) 9 (8.7%)
COPD 21 (15.7%) 24 (23.3%)
IPF 3 (2.2%) –
CHF 18 (13.5%) 44 (42.7%)
DM 20 (15%) 20 (19.4%)
Cancer 10 (7.5%) 6 (5.8%)
Note: *Patients had to change or add their antibiotic treatment. 
Abbreviations: CHF, coronary heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; IPF, interstitial pulmonary fibrosis; SD, standard deviation.
Table 2 Significant findings regarding influenza A (H1N1)-positive 
patients
Most H1N1-positive patients did not have chest X-ray  
findings upon admission
P , 0.001
Most H1N1-positive patients did not have chest X-ray  
findings upon discharge
P , 0.001
Respiratory distress upon admission was less common in 
H1N1 positive than in H1N1-negative patients 
P , 0.001
H1N1-positive patients were mainly administered macrolides P , 0.005
H1N1-positive patients used mainly protection measures P , 0.001
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Discussion
The major finding is that therapy for H1N1 incurred a higher 
cost compared with that for H1N1-negative infections. Of 
note, the cost was especially high during the first days of 
influenza, stabilizing at a lower level during the following 
days. The latter pattern is ascribable to the adoption of strict 
protection measures, according to the Hellenic Centre for 
Disease Control and Prevention guidelines.26 Indeed, while 
waiting for the swab results, all patients were treated with 
oseltamivir and medical staff had to keep using the afore-
mentioned protection measures. These were pursued until the 
result was available, which was no sooner than 48 hours. These 
observations concur with current experience. Despite accu-
rate diagnosis and prompt treatment, in one report numerous 
pathogens were wrongly diagnosed as influenza A (H1N1).27 
From a health system point of view, this misdiagnosis of 
influenza A (H1N1)/2009 may have led to the underestima-
tion of other serious conditions.28 For the same reason, a 
large number of patients is likely to have been unnecessarily 
treated with oseltamivir, resulting in not only unnecessary 
cost and patient exposure to the side effects of this agent but 
also overimplementation of infection control procedures in 
hospitals.29–31 Taken together, these findings underline and 
partly explain the high cost associated with H1N1.
In terms of protection measures, H1N1-positive patients 
incurred higher expenses. It should be emphasized that not 
only medical staff but also any visiting patients’ relatives 
employed costly protection measures. Therefore, frequent 
visits induced a higher cost due to the widespread use of pro-
tection measures. Additionally, the cost due to the extensive 
use of personal protective equipment is directly related to the 
bed design deficiencies observed in most negative-pressure 
chambers. In such chambers, patient medical monitoring is not 
automated, thus requiring regular visits by medical and nurs-
ing personnel, which, in turn, resulted in wide use of protective 
measures. Continuous monitoring and recording of patients’ 
vital signs is necessary to minimize the visits of medical staff 
and save cost on personal protective equipment.
In this study’s dataset, the cost of non-ICU ward care 
was approximately the same for both negative and positive 
patients. Conversely, the cost for hospitalization in the ICU 
was almost double for H1N1-positive patients, which was 
associated with more frequent virus-induced acute respira-
tory distress necessitating intubation and mechanical support. 
In general, though, admission to ICU led to a substantial 
increase in cost, due to the larger number of nursing staff 
and the use of special equipment.
Table 3 Cost analysis
H1N1 (+) H1N1 (−)
Days under oseltamivir 
75 mg
724 days 206 days
Total amount €4655.32 €1324.58 
Days of hospitalization* 841 days 829 days
Total amount €354902  €349838 
Protection measures 524 days 188 days
Total amount €188640  €67680 
ICU hospitalization*** 73 days 43 days
Total amount €41610  €24510 
Patients under macrolide  
treatment
96 (72.2%) 60 (58.3%)
608 days 501 days
Total amount €1927.36  €1588.17 
Patients under quinolone  
treatment
53 (39.8%) 43 (41.7%)
348 days 328 days
Total amount €2550.84  €2404.24 
Oxygen, cost/day No additional cost
Total amount
Aerosol therapy**** 306 days 253 days
Total amount €3427.2  €2833.6 
Patients diagnostic examinations
  Chest X-ray 464 X-rays 532 X-rays
  Total amount €2320  €2660 
  Blood biochemistry** During hospitalization
  Total amount €9812  €9671 
  Arterial blood gas 588 measurements 503 measurements
  Total amount €2352  €2012 
  Sputum culture 36 measurements 67 measurements
  Total amount €216 €402 
Total sum €610,117.72 €464,923.59
Notes: *In the days of ward (non-ICU) hospitalization cost the nursing care and 
nutrition is included; **In the blood biochemistry, complete blood count, glucose, 
electrolyte, renal, liver function test, C reactive protein, and procalcitonin are included. 
Reverse-transcriptase-polymerase chain reaction for the virus diagnosis not included; 
***Nursing care, materials used, and hospital day charge are included (pharmaceuticals 
not included); ****Pharmaceuticals used were namely budesonide and ipratropium 
bromide for four times daily with nebulizer.
Abbreviations: H1N1, influenza A; ICU, intensive care unit.
electrolyte, renal, liver function test, C-reactive protein, and 
procalcitonin, was €9812 for positive and €9671 for negative 
patients. The cost of sputum culture was €216 for positive 
and €402 for negative patients (Table 3).
Hospitalization cost
The cost of hospitalization was considered the same either 
in the negative pressure chambers or on the general medical 
wards. Nursing care and nutrition cost was the same. The major 
difference was the cost of protection measures used. For H1N1-
positive patients, €188,640 was spent, in contrast with €67,680 
for H1N1-negative patients. The overall cost of hospitalization 
was €354,902 for H1N1-positive patients and €349,838 for 
H1N1-negative patients. The ICU cost was €41,610 for positive 
and €24,510 for negative patients (Table 3).
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Moreover, the cost associated with diagnostic examina-
tions did not differ significantly between the two groups. 
This is largely due to the different clinical presentations 
of H1N1 and respiratory infection. Indeed, H1N1-positive 
patients had to undergo more regular blood-biochemistry 
examinations to monitor liver and renal function. Naturally, 
this increased cost, as reported in previous studies.15,19 
H1N1-negative patients had to be regularly monitored for 
C-reactive protein and white blood cell count to assess clinical 
course.32–34 Arterial blood gas examination was performed 
more commonly in the H1N1-positive patients due to fear 
of acute respiratory distress development.15,19 In contrast, 
H1N1-negative patients had their usual check due to the 
hypoxia associated with radiographic opacities. Chest X-ray 
observation was more expensive for the H1N1-negative group 
because of the necessity for continuous clinical evaluation. 
This was due to the initial chest X-ray findings, since all 
H1N1-negative patients exhibited opacities upon admission 
X-rays. These findings were attributed to bacterial respiratory 
infection, based on clinical and laboratory findings. In addi-
tion, H1N1-negative patients had more frequent sputum 
cultures to determine the pathogen. This contrasts with 
H1N1-positive patients, in whom radiographic opacities were 
less common and clinical suspicion of bacterial co-infection 
upon admission was rarely a problem. As might be expected 
from previous studies,12,14–16 H1N1-positive patients were 
younger in comparison with H1N1-negative patients.
A further issue to be discussed is the pharmaceuticals used 
and how these affect cost. The H1N1 influenza virus is known 
to induce a “cytokine storm,”35–39 giving rise to the endeavor 
at patient prophylaxis. Macrolides are well-known for their 
anti-inflammatory and immunomodulatory actions, mostly 
attributable to the inhibition of intracellular hemagglutinin 
HA0 proteolysis.40–44 This observation agrees with the finding 
that only a small proportion of H1N1 patients receiving mac-
rolides had to change antibiotic treatment. These agents could 
emerge as cost-effective when administered as first-line treat-
ment, independently of their antibiotic property, due to their 
additional immunomodulatory ability to control influenza.
The present analysis may have a number of   limitations. 
First, examinations of urine antigen for Legionella/
Streptococcus and antibodies for Mycoplasma, Legionella, 
Rickettsia, and Streptococcus were not available for all 
patients and could therefore not be included. Moreover, 
diagnostic examinations at the emergency department were 
not described separately for the two groups, as the patients 
were admitted and the cost was incorporated in their overall 
hospitalization cost. Finally, the two groups differ in their 
absolute numbers and, therefore, fewer patients with under-
lying respiratory disease are included in the H1N1-negative 
patients. However, patients with comorbidities are expected 
to be susceptible to H1N1, regardless of any bacterial co-
infection, due to the immunomodulating and inflammatory 
properties of the virus.35–38,42
Conclusion
Treatment for H1N1 incurred higher cost compared with that 
for respiratory infection. The main reasons for this higher 
cost include widespread use of protection measures for 
patients and health care professionals, as well as prolonged 
ICU hospitalization. These results suggest that implementa-
tion of an automated system to monitor patients isolated in 
negative-pressure chambers would be desirable to reduce 
cost in H1N1.
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